Dose Intensified Molecular Targeted Radiotherapy for Cancer-Lymphoma as a Paradigm

Seminars in Nuclear Medicine

Volumn 40, Issue 2, 2010, Pages 136-144

  DeNardo, Gerald ^a   DeNardo, Sally ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; IBRITUMOMAB TIUXETAN; PREDNISONE; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; VINCRISTINE SULFATE;

ADJUVANT THERAPY; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; DOSE INTENSIFICATION MOLECULAR TARGETED RADIOTHERAPY; DOSIMETRY; DRUG DOSE ESCALATION; FEBRILE NEUTROPENIA; FOLLICULAR LYMPHOMA; GLIOBLASTOMA; HAIR LOSS; HUMAN; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NONHODGKIN LYMPHOMA; OVARY CANCER; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RADIOIMMUNOTHERAPY; RADIOSENSITIVITY; REVIEW; SINGLE DRUG DOSE; SOLID TUMOR; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING;

ANIMALS; HUMANS; IMMUNOTHERAPY; LYMPHOMA; RADIATION DOSAGE; RADIOMETRY; RADIOTHERAPY; RADIOTHERAPY DOSAGE;

EID: 74849132453     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2009.10.005     Document Type: Review

References (92)

1. Ehrlich P., and Herter C.A. Ueber einige Verwendungen der Napthochinonsulfosaure. Z Physiol Chem 61 (1904) 379-392
2. Pressman D., and Korngold L. The in vivo localization of anti-Wagner-osteogenic sarcoma antibodies. Cancer 6 (1953) 619-623
3. Ettinger D.S., Dragon L.H., Klein J., et al. Isotopic immunoglobulin in an integrated multimodal treatment program for a primary liver cancer. A case report. Cancer Treat Rep 63 (1979) 131-134
4. Kohler G., and Milstein C. Continuous culture of fused cells secreting antibody of predefined specificity. Nature 256 (1975) 495-497
5. Carrasquillo J.A., Krohn K.A., Beaumier P., et al. Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat Rep 68 (1984) 317-328
6. Nadler L.M., Stashenko P., Hardy R., et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 40 (1980) 3147-3154
7. Miller R.A., Maloney D.G., Warnke R., et al. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 306 (1982) 517-522
8. DeNardo S.J., DeNardo G.L., O'Grady L.F., et al. Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies. Int J Biol Markers 2 (1987) 49-53
9. DeNardo S.J., DeNardo G.L., O'Grady L.F., et al. Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody. Antibody Immunoconj Radiophar 1 (1988) 17-33
10. 131I-Lym-1. Cancer Res 50 suppl 3 (1990) 1014-1016
11. Press O.W., Eary J.F., Badger C.C., et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 7 (1989) 1027-1038
12. McLaughlin P., Grillo-Lopez A.J., Link B.K., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16 (1998) 2825-2833
13. Witzig T.E., Gordon L.I., Cabanillas F., et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20 (2002) 2453-2463
14. Kaminski M.S., Zelenetz A.D., Press O.W., et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19 (2001) 3918-3928
15. Goodwin D.A., and Meares C.F. Pretargeting: General principles; October 10-12, 1996. Cancer 80 suppl 12 (1997) 2675-2680
16. Sharkey R.M., Cardillo T.M., Rossi E.A., et al. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med 11 (2005) 1250-1255
17. Weiden P.L., Breitz H.B., Press O., et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): Initial phase I/II study results. Cancer Biother Radiopharm 15 (2000) 15-29
18. Press O.W., Eary J.F., Gooley T., et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96 (2000) 2934-2942
19. Press O.W., Unger J.M., Braziel R.M., et al. A phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group Protocol S9911. Blood 102 (2003) 1606-1612
20. Armitage J.O. Treatment of non-Hodgkin's lymphoma. N Engl J Med 328 (1993) 1023-1030
21. Fisher R.I., Gaynor E.R., Dahlberg S., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328 (1993) 1002-1006
22. Rappaport H., Winter W.I., and Hicks E.B. Follicular lymphoma: A re-evaluation of its position in the scheme of malignant lymphoma, based on a survey of 253 cases. Cancer 9 (1956) 792-821
23. Lukes R.F., and Collins R.D. Immunologic characterization of human malignant lymphomas. Cancer 34 (1974) 1488-1503
24. Lennert K., Mohri N., Stein H., et al. The histopathology of malignant lymphoma. Br J Haematol 31 (1975) 193-204
25. The Non-Hodgkin's Lymphoma Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer 49 (1982) 2112-2135
26. Harris N.L., Jaffe E.S., Stein H., et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84 (1994) 1361-1392
27. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329 (1993) 987-994
28. Horning S.J. Treatment approaches to the low-grade lymphomas. Blood 83 (1994) 881-884
29. Gallagher C.J., Gregory W.M., Jones A.E., et al. Follicular lymphoma: Prognostic factors for response and survival. J Clin Oncol 4 (1986) 1470-1480
30. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346 (1995) 336-340
31. 90Y monoclonal antibodies 170H.82 with autologous stem cell support and cyclosporin A. Clin Cancer Res 5 suppl 10 (1999) 3243s-3248s
32. Wong J.Y.C., Somlo G., Odom-Maryon T., et al. Initial clinical experience evaluating Yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer. Clin Cancer Res 5 (1999) 3224s-3231s
33. Kapadia N.S., Engles J.M., and Wahl R.L. In vitro evaluation of radioprotective and radiosensitizing effects of rituximab. J Nucl Med 49 (2008) 674-678
34. Skvortsova I., Popper B.A., and Skvortsov S. Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells. J Radiat Res 46 (2005) 241-248
35. Coiffer B., Lepage E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 (2002) 235-242
36. Witzig T.E., White C.A., and Gordon L.I. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 21 (2003) 1263-1270
37. Witzig T.E., Flinn I.W., Gordon L.I., et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20 (2002) 3262-3269
38. Morschhauser F., Radford J., Van Hoof A., et al. Phase III Trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26 (2008) 5156-5164
39. Kaminski M., Tuck M., and Regan D. High response rates and durable remissions in patients with previously untreated, advanced-stage, follicular lymphoma treated with tositumomab and iodine I-131. Blood 100 (2002) 356a
40. Ghobrial I., and Witzig T. Radioimmunotherapy: A new treatment modality for B-cell non-Hodgkin's lymphoma. Oncology 18 (2004) 623-630
41. Juweid M., Sharkey R.M., Markowitz A., et al. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res 55 suppl 23 (1995) 5899s-5907s
42. 90Y-labeled humanized LL2 anti-CD22 monoclonal antibody (MAb) in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL). Clin Cancer Res 5 suppl (1999) 3292s-3303s
43. 131I-Lym-1 antibody. Cancer Biother Radiopharm 13 (1998) 239-254
44. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 16 (1998) 3246-3256
45. Kaminski M.S., Zasadny K.R., Francis I.R., et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14 (1996) 1974-1981
46. 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res 5 suppl 10 (1999) 3281s-3286s
47. Knox S.J., Goris M.L., Trisler K., et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 2 (1996) 457-470
48. Emmanouilides C., Witzig T.E., Wiseman G.A., et al. Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma. Cancer Biother Radiopharm 22 (2007) 684-691
49. DeNardo G.L. Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs). Semin Nucl Med 35 (2005) 202-211
50. DeNardo G.L., Sysko V.V., and DeNardo S.J. Cure of incurable lymphoma. Int J Radiat Oncol Biol Phys 66 (2006) S46-S56
51. Borghaei H., Wallace S., and Schilder R.J. Factors associated with toxicity and response to yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma 5 suppl 1 (2004) 16-21
52. DeNardo G.L., Schlom J., Buchsbaum D.J., et al. Rationales, evidence and design considerations in fractionated radioimmunotherapy. Cancer 94 (2002) 1332-1348
53. Ansell S.M., Ristow K.M., and Habermann T.M. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol 20 (2002) 3885-3890
54. 131I therapy in non-Hodgkin's lymphoma. J Nucl Med 46 (2004) 128S-140S
55. 131I-Lym-1 as a model. Cancer 73 suppl 3 (1994) 1038-1048
56. Liersch T., Meller J., Kulle B., et al. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-Labetuzumab after salvage resection of colorectal metastases in the liver: Five-year safety and efficacy results. J Clin Oncol 23 (2005) 6763-6770
57. Meredith R.F., Alvarez R.D., Partridge E.E., et al. Intraperitoneal radioimmunochemotherapy of ovarian cancer: A phase I study. Cancer Biother Radiopharm 16 (2001) 305-315
58. Zalutsky M.R. Targeted alpha-particle therapy of microscopic disease: Providing a further rationale for clinical investigation. J Nucl Med 47 (2006) 1238-1240
59. Wilder R.B., DeNardo G.L., and DeNardo S.J. Radioimmunotherapy: Recent results and future directions. J Clin Oncol 14 (1996) 1383-1400
60. Goldenberg D.M. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 43 (2002) 693-713
61. Emami B., Lyman J., Brown A., et al. Tolerance of normal tissue to therapeutic radiation. Int J Radiat Oncol Biol Phys 21 (1991) 109-122
62. 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: A phase I trial. Cancer Res 55 (1995) 5921s-5924s
63. 131I-labeled monoclonal antibody CC49 in breast cancer: A phase II trial. Clin Cancer Res 3 (1997) 1547-1555
64. Chatal J.F., Campion L., Kraeber-Bodere F., et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: A collaborative study with the French Endocrine Tumor Group. J Clin Oncol 24 (2006) 1705-1711
65. Liu S.Y., Eary J.F., Petersdorf S.H., et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 16 (1998) 3270-3278
66. Gopal A.K., Gooley T.A., Maloney D.G., et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin's lymphoma: A multivariable cohort analysis. Blood 102 (2003) 2351-2357
67. Meredith R.F., Khazaeli M.B., Liu T., et al. Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. J Nucl Med 33 (1992) 1648-1653
68. Schlom J., Molinolo A., Simpson J.F., et al. Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst 82 (1990) 763-771
69. DeNardo D.A., DeNardo G.L., Yuan A., et al. Prediction of radiation doses from therapy using tracer studies with iodine-131 labeled antibodies. J Nucl Med 37 (1996) 1970-1975
70. Shen S., DeNardo G.L., DeNardo S.J., et al. Reproducibility of operator processing for radiation dosimetry. Nucl Med Biol 24 (1997) 77-83
71. Stabin M.G. Update: The case for patient-specific dosimetry in radionuclide therapy. Cancer Biother Radiopharm 23 (2008) 273-284
72. Kaminski M.S., Estes J., Zasadny K.R., et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed refractory B-cell non-Hodgkin lymphoma: Update results and long-term follow-up of the University of Michigan experience. Blood 96 (2000) 1259-1266
73. 90yttrium radioimmunotherapy trial on non-Hodgkin's lymphoma (NHL). J Nucl Med 40 (1999) 64P
74. 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: A pilot study. Anticancer Res 18 (1998) 2779-2788
75. Wiseman G.A., Kornmehl E., Leigh B., et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: Combined data from 4 clinical trials. J Nucl Med 44 (2003) 465
76. Sharkey R.M. The direct route may not be the best way to home. J Nucl Med 46 (2005) 391-394
77. Axworthy D.B., Reno J.M., Hylarides M.D., et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA 97 (2000) 1802-1807
78. Weiden P.L., and Breitz H.B. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL). Crit Rev Oncol Hematol 40 (2001) 37-51
79. Press O.W., Corcoran M., Subbiah K., et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood 98 (2001) 2535-2543
80. Goldenberg D.M., Sharkey R.M., Paganelli G., et al. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 24 (2006) 823-834
81. Goldenberg D.M., and Sharkey R.M. Novel radiolabeled antibody conjugates. Oncogene 26 (2007) 3734-3744
82. Rossi E.A., Goldenberg D.M., Cardillo T.M., et al. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci USA 103 (2006) 6841-6846
83. Goldenberg D.M., Rossi E.A., Sharkey R.M., et al. Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med 49 (2008) 158-163
84. Hok S., Natarajan A., Balhorn R., et al. Synthesis and radiolabeling of selective high-affinity ligands designed to target non-Hodgkin's lymphoma and leukemia. Bioconjug Chem 18 (2007) 912-921
85. West J., Perkins J., Hok S., et al. Direct antilymphoma activity of novel, first-generation "antibody mimics" that bind HLA-DR10-positive non-Hodgkin's lymphoma cells. Cancer Biother Radiopharm 21 (2006) 645-654
86. Balhorn R., Hok S., Burke P., et al. Selective high affinity ligand antibody mimics for cancer diagnosis and therapy: Initial application to lymphoma/leukemia. Clin Cancer Res 13 suppl 18 (2007) 5621s-5628s
87. DeNardo G.L., Natarajan A., Hok S., et al. Nanomolecular HLA-DR10 antibody mimics: A potent system for molecular targeted therapy and imaging. Cancer Biother Radiopharm 23 (2008) 783-795
88. DeNardo G.L., Mirick G.R., Hok S., et al. Molecular specific and cell selective cytotoxicity induced by a novel synthetic HLA-DR antibody mimic for lymphoma and leukemia. Int J Oncol 34 (2009) 511-516
89. Maloney D.G., Grillo-Lopez A.J., White C.A., et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90 (1997) 2188-2195
90. DeNardo G.L., Kroger L.A., DeNardo S.J., et al. Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3). Cancer 73 (1994) 1012-1022
91. 90Y-DOTA-hLL2: An agent for radioimmunotherapy of non-Hodgkin's lymphoma. J Nucl Med 44 (2003) 77-84
92. Armitage J.O., and Weisenburger D.D. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. J Clin Oncol 16 (1998) 2780-2795